Modality
mRNA
MOA
SGLT2i
Target
GIP-R
Pathway
Proteasome
MCCMyelofibrosisGA
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Jul 2030
Phase 1Current
NCT08926716
1,520 pts·GA
2018-01→2030-07·Terminated
NCT05696239
1,302 pts·Myelofibrosis
2023-06→2028-08·Active
2,822 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-08-112.4y awayInterim· Myelofibrosis
2030-07-094.3y awayInterim· GA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Termina…
P1
Active
Catalysts
Interim
2028-08-11 · 2.4y away
Myelofibrosis
Interim
2030-07-09 · 4.3y away
GA
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08926716 | Phase 1 | GA | Terminated | 1520 | SeizFreq |
| NCT05696239 | Phase 1 | Myelofibrosis | Active | 1302 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |